文献速递肺结节与肺癌间质性肺疾病

肺癌合并间质性肺疾病的临床诊断与治疗

[Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2024-01-01

肺癌与间质性肺疾病(ILD)有相似危险因素与发病机制,共病发病率增高且预后差。本文综述共病早期诊断困难、治疗影响因素多,提出手术、放疗、化疗、靶向及免疫治疗的选择原则,并呼吁开展前瞻性临床试验。

要点

  • 早期肺癌合并ILD有手术指征者,应按肿瘤分期及肺功能经MDT决定术式与切除范围。
  • 不适合手术者需权衡放疗获益与并发症风险,选择合适方案及剂量。
  • 驱动基因突变阳性者选肺毒性低的靶向药;免疫治疗需密切监测免疫相关肺炎。

核心结论

  • 肺癌合并ILD共病早期诊断困难、治疗影响因素多、病死率高且预后差。
  • 肺癌治疗会增加共病患者ILD急性进展的风险,需按治疗方式个体化权衡。
  • 未来需前瞻性临床试验制定安全有效的共病治疗方案。

研究设计与样本

  • 本文为综述,围绕肺癌合并间质性肺疾病的临床诊断与治疗进行论述。

主要发现

  • 肺癌与ILD有相似的危险因素与发病机制,共病发病率及患病率增高。
  • 肺癌与ILD共病可能影响患者肺癌治疗方案的选择。
  • 部分化疗方案可能导致ILD急性进展,化疗方案选择尤为重要。
  • 肺癌合并ILD患者可从免疫治疗中获益,但免疫相关肺炎发生风险增高。

关键数值与推荐

  • 早期肺癌合并ILD有手术指征者,根据肿瘤分期及肺功能在MDT基础上决定手术方式及切除范围。
  • 早期肺癌合并ILD不适合手术者,权衡放疗获益及并发症发生风险,选择合适放疗方案及剂量。
  • 晚期肺癌合并ILD患者化疗有效,但部分化疗方案可能导致ILD急性进展。
  • 驱动基因突变阳性的肺癌合并ILD患者,应选用肺毒性低的靶向药物。
  • 肺癌合并ILD患者免疫治疗中需密切监测不良反应的发生。

临床怎么用

  • 共病患者启动肺癌治疗前应评估ILD急性进展风险并个体化选择方案。
  • 手术决策需经MDT结合肿瘤分期与肺功能确定术式及切除范围。
  • 放疗需权衡获益与并发症风险后确定方案及剂量。
  • 靶向治疗优先选用肺毒性低的药物。
  • 免疫治疗期间密切监测免疫相关肺炎等不良反应。

局限性

  • 本文为综述,未报告原始研究数据。
  • 原文指出未来需要开展前瞻性临床试验以制定合理有效的治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer and interstitial lung disease have similar risk factors and pathogenesis. The incidence of lung cancer associated with interstitial lung disease is increasing, and the problem of comorbidity has gradually attracted attention. Early diagnosis of lung cancer associated with interstitial lung disease is difficult, there are many factors influencing treatment, and the prognosis is poor. Interstitial lung disease affects the treatment options for lung cancer in comorbid patients, and lung cancer treatment will increase the risk of acute exacerbation of interstitial lung disease in comorbid patients. For patients with early-stage lung cancer complicated with interstitial lung disease who have surgical indications, the surgical method and extend of resection should be determined on the basis of MDT according to tumor stage and lung function. For patients with early-stage lung cancer combined with interstitial lung disease who are not suitable for surgery, the benefits and risks of complications of the radiotherapy should be weighed, and the appropriate radiotherapy regimen and dose should be selected. Chemotherapy is an effective treatment for patients with advanced lung cancer complicated with interstitial lung disease. Some chemotherapy regimens cause acute progression of interstitial lung disease, and the choice of chemotherapy regimen is particularly important. For lung cancer patients with interstitial lung disease who are positive for driver gene mutations, targeted drugs with low pulmonary toxicity should be selected. Patients with lung cancer combined with interstitial lung disease may benefit from immunotherapy, but the risk of immune-related pneumonia is increased. The occurrence of adverse reactions should be closely monitored during immunotherapy. In the future, more prospective clinical trials are needed to formulate reasonable and effective treatment regimens for lung cancer combined with interstitial lung disease to achieve a better prognosis. 肺癌与间质性肺疾病(ILD)有相似的危险因素与发病机制,肺癌合并间质性肺疾病的发病率及患病率增高,二者共病问题已逐渐引起临床重视。肺癌与ILD共病早期诊断困难,治疗影响因素多,病死率高,患者预后差。肺癌与ILD共病可能影响患者肺癌治疗方案的选择,同时肺癌的治疗措施也会增加共病患者ILD急性进展的风险。早期肺癌与ILD共病患者若有手术指征,应根据肿瘤分期及肺功能,在MDT基础上决定手术方式及切除范围;若不适合手术,应权衡放疗获益及并发症发生风险,选择合适放疗方案及剂量。化疗是晚期肺癌与ILD共病患者有效的治疗方案,但部分化疗方案可能导致ILD急性进展,因此化疗方案的选择尤为重要。对于驱动基因突变阳性的肺癌与ILD共病患者,应选用肺毒性低的靶向药物。肺癌与ILD共病患者可以从免疫治疗中获益,但免疫相关肺炎的发生风险增高,免疫治疗中需要密切监测不良反应的发生。未来需要开展前瞻性临床试验,制定对于肺癌与ILD共病患者安全有效的治疗方案,使其获得更好的疗效及预后。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xu Y. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 39497386. doi:10.3760/cma.j.cn112147-20240519-00269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。